Johanna C. Bendell

Sarah Cannon — United States

Medicine · Health Sciences

82h-index30.1kcitations928works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(310), Cancer Immunotherapy and Biomarkers(204), Lung Cancer Treatments and Mutations(127), Gastric Cancer Management and Outcomes(127), Cancer Treatment and Pharmacology(114)

Publications925 total

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer
Nature Communications·2025· 10 citedOpen Access
Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Data from First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2025Open Access
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Molecular Cancer Therapeutics·2024· 2 citedOpen Access
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
Immunotherapy·2024· 5 citedOpen Access
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
JAMA Oncology·2023· 59 citedOpen Access
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer
Nature Communications·2023· 33 citedOpen Access
Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial
Frontiers in Oncology·2023· 8 citedOpen Access
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
The Lancet Oncology·2023· 219 cited
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
British Journal of Cancer·2023· 27 citedOpen Access
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Cancer Immunology Immunotherapy·2023· 90 citedOpen Access
Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
2023Open Access
Supplementary Tables 1 and 2 and Supplementary Figures 1 and 2 from A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
2023Open Access
Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
2023Open Access
Supplementary Material from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
2023Open Access
Supplementary Tables 1 and 2 and Supplementary Figures 1 and 2 from A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
2023Open Access
Data from Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
2023Open Access
Data from A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
2023Open Access
Data from A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal Cancer
2023Open Access
Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
2023Open Access
page 1 of 47Next →

Frequent Co-authors

Howard A. Burris(10), Jeffrey R. Infante(10), Suzanne F. Jones(7), Zev A. Wainberg(7), Eric Van Cutsem(6), Michael A. Morse(6), Herbert I. Hurwitz(6), Thierry André(5), Razelle Kurzrock(5), Tae Won Kim(4), Élena Elez(4), Dung T. Le(4), Takayuki Yoshino(4), Ian Chau(4), Salvatore Siena(4), Gerald S. Falchook(4), Keith T. Flaherty(4), Charles S. Fuchs(4), Heinz‐Josef Lenz(4), Christopher G. Willett(4)